Want to see AU:IPD full AI Analyst Report?

Impedimed Limited (IPD) Price & Analysis

29 Followers

IPD Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.06

Previous CloseN/A

Volume149.09K

Average Volume (3M)853.05K

Market Cap

AU$18.30M

Enterprise ValueAU$17.12M

Total Cash (Recent Filing)AU$18.85M

Total Debt (Recent Filing)AU$21.93M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Aug 27, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding3,659,805,400

10 Day Avg. Volume551,953

30 Day Avg. Volume853,052

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)3.45

Price to Sales (P/S)5.55

P/FCF Ratio-4.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.02

Price Target Upside-16.67% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$22.43M

Bulls Say, Bears Say

Bulls Say

High Gross MarginSustained gross margin of ~86% indicates the BIS device business has high structural product-level profitability and pricing power versus direct costs. That margin buffer supports reinvestment in sales, clinical validation and product development over the next 2–6 months.

Consistent Revenue GrowthRevenue growth (reported 10.23% year and fundamentals showing higher-period growth) points to expanding adoption of BIS devices. Persistent top-line momentum supports installed-base expansion and recurring consumable or software revenue that can compound over several quarters.

Manageable LeverageA debt-to-equity around 0.71 implies conservative borrowing relative to equity, leaving financial flexibility to fund clinical studies, go-to-market investments or capital needs without immediate refinancing pressure over the medium term.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flows and a deteriorating FCF growth rate (-20.73%) signal structural cash burn. This constrains ability to self-fund commercialization or R&D and increases reliance on external financing over the coming months.

Weak Overall ProfitabilityNegative EBIT and net margins show that operating expenses and overhead absorb gross profits. Unless operating leverage improves, profitability will remain weak, limiting free cash flow conversion and shareholder returns over the medium term.

Negative Return On EquityA negative ROE indicates the company is not currently generating returns on shareholder capital, reflecting operational losses and capital inefficiency. This structural issue can hinder investor confidence and raise capital costs for necessary future funding.

Impedimed Limited News

Impedimed Issues 1.8 Billion Follow-On Options in Major Capital Move

Impedimed Limited ( ($AU:IPD) ) just unveiled an announcement. Impedimed Limited has notified the market of the issue...

5d ago

ImpediMed Director Increases Stake via Tranche 2 Placement

The latest announcement is out from Impedimed Limited ( ($AU:IPD) ). ImpediMed Limited has disclosed a change in...

14d ago

ImpediMed director boosts stake via placement-linked share and option issue

The latest update is out from Impedimed Limited ( ($AU:IPD) ). ImpediMed director Ms Janelle Delaney has significantly...

14d ago

ImpediMed Director Deepens Stake via Tranche 2 Share Placement

Impedimed Limited ( ($AU:IPD) ) has issued an announcement. ImpediMed has disclosed a significant change in the holdings...

14d ago

ImpediMed director vastly increases stake through approved share placement

Impedimed Limited ( ($AU:IPD) ) has shared an announcement. ImpediMed Limited has disclosed a substantial change in the...

14d ago

ImpediMed Reveals Top Holders for Newly Quoted ASX Options

Impedimed Limited ( ($AU:IPD) ) has issued an announcement. ImpediMed Limited has released details of its two new...

15d ago

ImpediMed Confirms Compliance as It Issues 1.32 Billion New Shares

An update from Impedimed Limited ( ($AU:IPD) ) is now available. ImpediMed Limited has issued 1,320,433,800 new fully...

15d ago

Impedimed Seeks ASX Quotation for Massive New Share and Option Issuance

Impedimed Limited ( ($AU:IPD) ) has shared an announcement. Impedimed Limited has applied for quotation on the ASX...

15d ago

ImpediMed raises A$2.1m in oversubscribed share purchase plan

Impedimed Limited ( ($AU:IPD) ) has provided an announcement. ImpediMed Limited has completed an oversubscribed share purchase plan...

21d ago

ImpediMed Director Receives Equity in Lieu of Board Fees

Impedimed Limited ( ($AU:IPD) ) has shared an update. ImpediMed Limited has issued 69,690 ordinary shares to non-executive...

28d ago

IPD FAQ

What was Impedimed Limited’s price range in the past 12 months?

Impedimed Limited lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.

What is Impedimed Limited’s market cap?

Impedimed Limited’s market cap is AU$18.30M.

When is Impedimed Limited’s upcoming earnings report date?

Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 57 days.

How were Impedimed Limited’s earnings last quarter?

Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of -AU$0.002 by -AU$0.004.

Is Impedimed Limited overvalued?

According to Wall Street analysts Impedimed Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Impedimed Limited pay dividends?

Impedimed Limited does not currently pay dividends.

What is Impedimed Limited’s EPS estimate?

Impedimed Limited’s EPS estimate is 0.

How many shares outstanding does Impedimed Limited have?

Impedimed Limited has 3,659,805,400 shares outstanding.

What happened to Impedimed Limited’s price movement after its last earnings report?

Impedimed Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of -AU$0.002. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Impedimed Limited?

Currently, no hedge funds are holding shares in AU:IPD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Impedimed Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-165.13%

Trailing 12-Months

Asset Growth

5.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Impedimed Limited

Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.

Impedimed Limited (IPD) Earnings & Revenues

Historic Earnings Reports

IPD Stock 12 Month Forecast

Average Price Target

AU$0.02

▼(-16.67% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.02,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.016666666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.01,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.014,0.014461538461538461,0.014923076923076923,0.015384615384615385,0.015846153846153847,0.016307692307692308,0.01676923076923077,0.01723076923076923,0.01769230769230769,0.018153846153846152,0.018615384615384617,0.019076923076923078,0.01953846153846154,{"y":0.02,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.014,0.014205128205128205,0.01441025641025641,0.014615384615384615,0.01482051282051282,0.015025641025641025,0.015230769230769232,0.015435897435897437,0.01564102564102564,0.015846153846153847,0.01605128205128205,0.016256410256410257,0.01646153846153846,{"y":0.016666666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.014,0.013692307692307693,0.013384615384615385,0.013076923076923076,0.012769230769230769,0.012461538461538461,0.012153846153846154,0.011846153846153847,0.011538461538461539,0.011230769230769232,0.010923076923076924,0.010615384615384615,0.010307692307692308,{"y":0.01,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.033,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.039,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.047,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.039,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.037,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.038,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.036,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.036,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.017,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.014,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.014,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >